DOCSLIB.ORG

17Th European Society for Biomedical Research on Alcoholism Congress 21-24 September 2019, Lille – Invited Talks and Symposia Abstracts

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
17Th European Society for Biomedical Research on Alcoholism Congress 21-24 September 2019, Lille – Invited Talks and Symposia Abstracts Directeur de la rédaction Pr François Paille Rédacteur en chef Pr Amine Benyamina Rédacteurs associés Dr Philippe Batel Dr Ivan Berlin Dr Laurent Karila Pr Michel Lejoyeux Pr Mickaël Naassila Rédactrice Sciences humaines Pr Myriam Tsikounas Rédactrice Sciences psychologiques Pr Isabelle Varescon-Pousson Comité de rédaction Pr Georges Brousse Pr Olivier Cottencin Dr Michel Craplet Pr Jean-Bernard Daeppen Dr Jean-Michel Delile Pr Maurice Dematteis Dr Claudine Gillet th Dr Geneviève Lafaye 17 European Society for Biomedical Research Pr Michel Reynaud Dr Alain Rigaud Dr Marc Valleur on Alcoholism Congress Directeur de la publication Pr Mickael Naassila 21-24 September 2019, Lille Comité scientifique Pr Jean Adès Pr Thomas F. Babor Pr Jean-Louis Balmès Pr Maurice Bazot Dr Mats Berglund Pr Jacques Besson Pr Jean-Pierre Blayac Pr Jonathan D. Chick Mme Marie Choquet Pr Philippe de Witte Pr Michel Escande Pr Claude Got Dr Antoni Gual Pr Momar Gueye Pr Roger Henrion Pr Denise Kandel Pr Michel Le Moal Pr Karl Mann Mme Véronique Nahoum-Grappe Dr José Maria Neves Cardoso Pr Philippe-Jean Parquet Pr Jean-Louis Pedinielli Pr Falvio Poldrugo Pr Bernard Roques Pr John A. Talbott Pr Jean-Luc Vénisse Pr Lars von Knorring Pr Jacques Weill Pr Jean-Jacques Yvorel ISSN 2554-4853 Trimestriel Société Française PRINCEPS Éditions SEPTEMBRE-DÉCEMBRE 2019 - Tome 41, n° 3-4 d’Alcoologie !BSTRACTS CONGRÈS Pr Mickael Naassila* * President 17th ESBRA Meeting 17th European Society for Biomedical Research on Alcoholism congress 21-24 September 2019, Lille – Invited talks and Symposia abstracts Invited talks forward, such as combining training with neurostimulation. Together these fndings emphasize the malleability of the addicted brain and the promise of targeted CT in the treat- Targeting biased decision making in the treatment ment of AUD. of alcohol use disorders Reinout Wiers (Amsterdam, The Netherlands) ASH-NASH synergism and its underlying mechanisms Alcohol Use Disorder (AUD) and other addictions have been Hidekazu Tsukamoto (Los Angeles, USA) characterized as a chronic brain disease from the biomedical perspective and as the unfortunate outcome of adverse social Alcohol misuse and obesity are two leading independent risk conditions from the social science perspective. We emphasize factors for alcoholic and non-alcoholic steatohepatitis (ASH biased decision making as a central characteristic in (alcohol) and NASH) around the globe. Synergistic interactions by addiction. From a therapeutic perspective, the important these factors have also increasingly been recognized. In fact, question is to what extent these biases reverse after successful the emerging evidence indicates the average BMI of some abstinence, and to what extent they can be reversed through ASH patient populations in the US may be around 30. ASH targeted training. Two types of Cognitive Training (CT) and alcoholic cirrhosis occur as the consequences of alco- can be distinguished: those in which general abilities are hol addiction which dictates heavy drinking and sustained trained (e.g., working memory training) and those in which blood alcohol levels (BAL) due to physical dependence. Tis initial motivational reactions to alcohol are targeted, so called condition can be reproduced in rodents by intragastric fee- cognitive biases (Cognitive Bias Modifcation, CBM, Wiers ding of ethanol diet which also allows precise reproduction 2018). I will review the state of afairs in both. Training of of the synergism between sustained BAL and overfeeding- general abilities takes a long time, but does show promise for induced obesity. Tis model exhibits heightened steatohepa- a subgroup of patients. CBM has shown to increase one-year titis, M1 macrophage activation, nitrosative stress driven by abstinence in several large clinical trials, with efect sizes Notch-dependent mitochondrial metabolic reprogramming. similar to medication for alcohol (NNT=12). It is also beco- Moderate alcohol intake may also synergistically work with ming clear for which individuals CBM shows most promise NASH to promote liver cancer development. Evidence sug- as an add-on treatment (those with a strong cue-reactivity gests social drinking is sufcient enough to promote live can- and/or impulsivity), and we are beginning to understand cer incidence in NASH-cirrhosis patients. Tis synergism is the neurocognitive mechanisms underlying training efects reproduced in mice injected with the hepatocarcinogen DEN (e.g., reduced cue-reactivity). CT shows modest but reliable and fed alcohol-containing Western diet. Tumor promotion efects as add-on to regular psychosocial treatment, but does in this model is dependent on activation of hepatic stellate not appear to work in the absence of psychosocial treatment, cells (HSC) driven by Wnt--catenin-mediated overexpres- nor in the absence of motivation to change (e.g. in proof- sion of stearoyl-CoA-desaturase (SCD), which in turn esta- of-principle studies in students). Finally, I will sketch ways blishes a SCD-LRP5/6-Wnt positive loop to amplify Wnt- Alcoologie et Addictologie. 2019 ; 41 (3) : 232-282 232 Congress -catenin pathway in HSC and tumor microenvironment, etheno DNA-adducts and the severity of fbrosis. First results leading to tumor-promoting lipid metabolic reprogramming. of the efect of CYP2E1 inhibition by chlormethiazole, a Tese fndings highlight the causal roles of morphogen- specifc CYP2E1 inhibitor on ALD can be expected soon. driven metabolic reprogramming in steatohepatitis and liver tumor development promoted by ASH-NASH synergism. Young investigator symposium Applying precision medicine to alcohol and drug use disorders Henry R Kranzler1 (1 Philadelphia, USA) Nicotine increases alcohol self-administration via µ-opioid receptor activity in the ventral tegmental Although most medications approved to treat alcohol use area disorder (AUD) and opioid use disorder (OUD) have been E. Domi1, A. Hansson2, P. Marvin2, E.Barbier1, Xu Li1, E. Augier1, shown to be efcacious in placebo-controlled trials, efect M. Heilig1 (1 Linkoping, Sweden, 2 Mannheim, Germany) sizes vary among them. Even medications with the largest efect sizes, however, are not efcacious for all (or perhaps Alcohol and nicotine are the most commonly co-abused even most) patients treated with them. Recent eforts to en- drugs, with a large majority of alcoholics diagnosed with a hance the therapeutic efects of these medications have used comorbid addiction to nicotine. Te endogenous opioid sys- a precision medicine approach, including the use of pharma- tem is involved in the rewarding properties of both alcohol cogenetics (PGx) to identify genetic predictors of treatment and nicotine. We previously found that CERC-501, a highly response. Tis lecture will discuss recent developments in the selective KOR antagonist reduced escalated alcohol self-ad- PGx of AUD and OUD. Specifc topics to be covered are: ministration induced by the intermittent access to alcohol 1) a variant in the mu-opioid receptor gene (OPRM1) and 20%. In here we tested the efect of CERC-501 on escalation response to naltrexone treatment of AUD, 2) a variant in the of alcohol drinking induced by nicotine. Chronic nicotine eli- kainate receptor gene and response to topiramate treatment cited a robust and specifc escalation of alcohol drinking wit- of AUD, 3) a variant near OPRM1 and usual methadone hout afecting saccharin self-administration and locomotion. dose for treating OUD, and 4) a variant in the delta-opioid CERC-501 did not suppress nicotine-induced increased alco- receptor gene (OPRD1) and response to buprenorphine hol self-administration in opposite to naltrexone which bloc- treatment of OUD. Findings from these studies underscore ked escalated drinking. Our in situ hybridization data showed the potential utility of a precision medicine approach to trea- a diferent pattern of expression and functional activation of ting alcohol and drug use disorders and some of the obstacles MORs in alcohol escalation induced by nicotine, while KORs to be overcome in advancing the feld. expression and activity was not afected by the combination The role of CYP2E1 in alcoholic liver disease and of the two drugs. Specifcally, our data showed an increased expression and a decreased function of MORs in the ventral alcohol mediated carcinogenesis 1 1 1 tegmental area of alcohol-escalated rats. Nicotine induced Helmut K. Seitz , Sebastian Mueller ( Heidelberg, Germany) escalation of alcohol self-administration was also accompa- nied by decreased p-DARPP32 in nucleus accumbens shell. Various factors are involved in the pathogenesis of alcoholic Tis suggest that nicotine pretreatment reduces the rewarding liver disease (ALD) and ethanol mediated carcinogenesis. In value of alcohol and therefore mediates alcohol escalation. addition to genetic, epigenetic and immunologic mechanisms, In conclusion our results also suggest that targeting µ rather acetaldehyde associated toxicity, oxidative stress as well as than −opioid receptors may represent a promising phar- cytokine mediated infammation are of major importance. macotherapeutic approach for the treatment of alcohol use Oxidative stress with the generation of reactive oxygen spe- disorders where alcohol consumption is driven by nicotine. cies (ROS) develops either in infammation (alcoholic hepa- titis) or during oxidation of ethanol via cytochrome P4502E1 Unveiling the alcohol-dependent alterations of (CYP2E1). CYP2E1 is induced by ethanol, oxidizes ethanol local translation in
Load more

Recommended publications
  • The Effect of the Roots of Empathy Program on the Use of Psychotropic Medications Among Youth in Manitoba
    The effect of the Roots of Empathy program on the use of psychotropic medications among youth in Manitoba by Lindsey Dahl A Thesis submitted to the Faculty of Graduate Studies of The University of Manitoba in partial fulfilment of the requirements of the degree of MASTER OF SCIENCE Department of Community Health Sciences, Rady Faculty of Health Sciences, Max Rady College of Medicine University of Manitoba Winnipeg Copyright © 2017 by Lindsey Dahl Abstract Background: Psychotropic medications prescriptions to youth have increased. Roots of Empathy (ROE) is a social and emotional learning program that may influence the use of psychotropic medication. Methods: Administrative data was analyzed in a matched sample of children who received ROE during 2002/03 to 2012/13. Kaplan-Meier survival curves and Cox proportional hazard models were used to estimate the association between ROE and psychotropic medication dispensations. Results: Few significant differences were observed. Children who received ROE in kindergarten to grade 3 had a lower adjusted hazard for an anxiolytic dispensation. Children who received ROE in grade 7 to 8 had a higher hazard for an antipsychotic dispensation. Males who received the program had an increased hazard for an antipsychotic dispensation. Conclusion: There was no consistent differences in the likelihood of being dispensed a psychotropic medication between children who received ROE and children who did not in Manitoba. ii Acknowledgments I would like to first thank my thesis advisor Dr. Randy Fransoo of the Department of Community Health Sciences, Rady Faculty of Health Sciences, Max Rady College of Medicine at the University of Manitoba. Right from our initial meeting, Dr.
    [Show full text]
  • Screening of 109 Neuropeptides on Asics Reveals No Direct Agonists
    www.nature.com/scientificreports OPEN Screening of 109 neuropeptides on ASICs reveals no direct agonists and dynorphin A, YFMRFamide and Received: 7 August 2018 Accepted: 14 November 2018 endomorphin-1 as modulators Published: xx xx xxxx Anna Vyvers, Axel Schmidt, Dominik Wiemuth & Stefan Gründer Acid-sensing ion channels (ASICs) belong to the DEG/ENaC gene family. While ASIC1a, ASIC1b and ASIC3 are activated by extracellular protons, ASIC4 and the closely related bile acid-sensitive ion channel (BASIC or ASIC5) are orphan receptors. Neuropeptides are important modulators of ASICs. Moreover, related DEG/ENaCs are directly activated by neuropeptides, rendering neuropeptides interesting ligands of ASICs. Here, we performed an unbiased screen of 109 short neuropeptides (<20 amino acids) on fve homomeric ASICs: ASIC1a, ASIC1b, ASIC3, ASIC4 and BASIC. This screen revealed no direct agonist of any ASIC but three modulators. First, dynorphin A as a modulator of ASIC1a, which increased currents of partially desensitized channels; second, YFMRFamide as a modulator of ASIC1b and ASIC3, which decreased currents of ASIC1b and slowed desensitization of ASIC1b and ASIC3; and, third, endomorphin-1 as a modulator of ASIC3, which also slowed desensitization. With the exception of YFMRFamide, which, however, is not a mammalian neuropeptide, we identifed no new modulator of ASICs. In summary, our screen confrmed some known peptide modulators of ASICs but identifed no new peptide ligands of ASICs, suggesting that most short peptides acting as ligands of ASICs are already known. Acid-sensing ion channels form a small family of proton-gated ion channels that belongs to the degenerin/epi- thelial Na+ channel (DEG/ENaC) gene family1.
    [Show full text]
  • List of Registred Drugs in Armenia (01.03.2017-31.03.2017)
    LIST OF REGISTRED DRUGS IN ARMENIA (01.03.2017-31.03.2017) International nonproprietary name Dose and Registration Term of Legal Status N Trade name Drug form Manufacturer Country ATC1 code License holder (generic) or active packaging number registration for Supply ingredients name Eli Lilly Regional Lilly France S.A.S., Operations GmbH., solution for 100IU/ml, Zone Industrielle, 2 17.03.2017 1 Abasaglar insulin glargine France A10AE04 16535 PoM2 Koelblgasse 8-10, injection 3ml cartridges (5) rue du Colonel Lilly, 17.03.2022 1030, Vienna, 67640 Fegersheim Austria Olainfarm JSC, 5 300mg, Olainfarm JSC, 5 06.03.2017 Rupnicu Str., 2 Adaptol mebicar capsules hard in blister (20/2x10/, Rupnicu Str., Olaine, Latvia N06BX21 16440 PoM 06.03.2022 Olaine, LV-2114, 30/3x10/, 40/4x10/) LV-2114 Latvia Olainfarm JSC, 5 Olainfarm JSC, 5 500mg, 06.03.2017 Rupnicu Str., 3 Adaptol mebicar tablets Rupnicu Str., Olaine, Latvia N06BX21 16441 PoM in blister (20/2x10/) 06.03.2022 Olaine, LV-2114, LV-2114 Latvia 10mg, Pharmstandard- OTCPharm PJSC, fabomotizole in blisters Leksredstva JSC, 27.03.2017 123317, Moscow, 4 Afobazol (fabomotizole tablets (30/1x30/, 60/3x20/, 305022, Kursk, Russia N05BX04 14729/2 PoM 30.07.2020 Testovskaya str., 10, dihydrochloride) 60/2x30/, 90/3x30/, Agregatnaya 2nd str., Russia 120/4x30/) 1a/18 Gedeon Richter 15mg/g, Gedeon Richter PLC, 17.03.2017 PLC, Gyomroi ut 5 Airtal aceclofenac cream 60g aluminium Gyomroi ut 19-21, Hungary M01AB16 16514 OTC3 17.03.2022 19-21, 1103 tube 1103 Budapest Budapest, Hungary 1 Gedeon Richter PLC, Gyomroi ut 19-21, 1103 Budapest - batch releaser, Industrias Gedeon Richter Farmaceuticas powder for oral 100mg, 17.03.2017 PLC, Gyomroi ut 6 Airtal aceclofenac Almirall S.L., Ctra.
    [Show full text]
  • Drug Use Sequencing and Kandel's Gateway Hypothesis John Reid Clemson University, [email protected]
    Clemson University TigerPrints All Theses Theses 8-2008 Drug Use Sequencing and Kandel's Gateway Hypothesis John Reid Clemson University, [email protected] Follow this and additional works at: https://tigerprints.clemson.edu/all_theses Part of the Sociology Commons Recommended Citation Reid, John, "Drug Use Sequencing and Kandel's Gateway Hypothesis" (2008). All Theses. 447. https://tigerprints.clemson.edu/all_theses/447 This Thesis is brought to you for free and open access by the Theses at TigerPrints. It has been accepted for inclusion in All Theses by an authorized administrator of TigerPrints. For more information, please contact [email protected]. DRUG USE SEQUENCING AND KANDEL'S GATEWAY HYPOTHESIS A Thesis Presented to the Graduate School of Clemson University In Partial Fulfillment of the Requirements for the Degree Master of Science Applied Sociology by John Matthew Reid August 2008 Accepted by: Dr. Brenda Vander Mey, Committee Chair Dr. Douglas Kinly Sturkie Dr. Margaret Tina Britz i ABSTRACT This thesis tests the hypothesis by Kandel (1975) that there is a specific sequence of drug use that users follow. Using the same scalogram analysis technique utilized by Kandel in her original Gateway Hypothesis study, a distinct sequence of use was discovered. This thesis is based on the National Survey on Drug Use and Health (2005). This study confirmed Kandel’s earlier findings in that this study determined that there is a sequence of drug use. The current study also confirms Kandel’s position that licit drugs precede the use of illicit drugs. This study’s findings differ from those of Kandel, however, in that tobacco and not alcohol was found to be the first drug of experimentation.
    [Show full text]
  • A Molecular Basis for Nicotine As a Gateway Drug
    The new england journal of medicine special article shattuck lecture A Molecular Basis for Nicotine as a Gateway Drug Eric R. Kandel, M.D., and Denise B. Kandel, Ph.D. From the Howard Hughes Medical Insti- n the historic occasion of the 122nd Shattuck Lecture and tute (E.R.K.), Kavli Institute for Brain Sci- the 200th anniversary of the New England Journal of Medicine, we chose to ad- ence (E.R.K.), and the Departments of Neuroscience (E.R.K.) and Psychiatry Odress a topic that is at once scientific and personally historic. In recent (E.R.K., D.B.K.), College of Physicians debates over legalizing marijuana, from all-out acceptance in Colorado to narrow and Surgeons, and Mailman School of decriminalization in Maryland, the scientific question of the role of marijuana as a Public Health (D.B.K.), Columbia Univer- sity, and the New York State Psychiatric gateway drug (i.e., a drug that lowers the threshold for addiction to other agents) Institute (D.B.K.) — all in New York. Ad- has loomed large. Both opponents and proponents of legalization have distorted dress reprint requests to Dr. E. Kandel at what science does and does not tell us — and both sides have overlooked the im- the Department of Neuroscience, Col- lege of Physicians and Surgeons, Colum- portance of nicotine as a gateway drug. bia University, 1051 Riverside Dr., Unit Epidemiologic studies have shown that nicotine use is a gateway to the use of 87, New York, NY 10032, or at erk5@ marijuana and cocaine in human populations.
    [Show full text]
  • 2016 and Over 4,000 Research Scientists, 168 Scientific Leaders and 60,000 Was Our Leader and Guiding Light, Providing Inspiration and Moti- Pression
    INVEST IN MENTAL HEALTH ANNUAL REPORT 2 0 1 6 Dear Brain & Behavior Research Foundation Supporters: From mental illness to mental health–30 years of achievements by tremendous impact on psychiatric research and treatment. Connie problems improves symptoms of some patients with refractory de- The Foundation is proud of our accomplishments in 2016 and over 4,000 research scientists, 168 scientific leaders and 60,000 was our leader and guiding light, providing inspiration and moti- pression. In a study of patients with treatment-resistant depression, we are excited to focus on the promising path of discovery. With donors. We are proud to present you with our 2016 annual report vation to all who ever had the honor and privilege of knowing and about two thirds had metabolic deficiencies that affect the brain’s your sustained commitment, we will accelerate the funding of our and invite you to invest in mental health. working with her. She will be dearly missed by us all. But her legacy ability to produce neurotransmitters. Dr. Pan’s research found Grants and continue to lead the field with breakthroughs that continues with each new scientist which we support and each new that patients’ depression symptoms declined significantly when improve the lives of those living with mental illness. Thank you for Since 1987, the Brain & Behavior Research Foundation has invest- discovery which improves people’s lives. their metabolic problems were treated. Some of the patients even continuing the journey with us. ed in the future. We support the innovative brain and behavior reached remission. The most common of the deficiencies observed research today which will lead to new treatments and eventual While we are proud of our accomplishments, there is still much in the participants was in levels of cerebral folate, which is treat- Sincerely, cures in the future.
    [Show full text]
  • LIST of REGISTRED DRUGS in ARMENIA (Up to 31.12.2017)
    LIST OF REGISTRED DRUGS IN ARMENIA (Up to 31.12.2017) International nonproprietary Registration Term of Legal status for N Trade name name (generic) or Drug form Dose and packaging Manufacturer Country ATC1 code License holder number registration supply active ingredients name Lek Pharmaceuticals pefloxacin Lek Pharmaceuticals 400mg, 10.03.2015 d.d., Verovskova Str. 1 Abaktal (pefloxacin tablets film-coated d.d., Verovskova Str. Slovenia J01MA03 14308 PoM2 in blister (10/1x10/) 10.03.2020 57, 1526 Ljubljana, mesylate dihydrate) 57, 1526 Ljubljana Slovenia Lilly France S.A.S., Eli Lilly Regional 100IU/ml, Zone Industrielle, 2 17.03.2017 Operations GmbH., 2 Abasaglar insulin glargine solution for injection France A10AE04 16535 PoM 3ml cartridges (5) rue du Colonel Lilly, 17.03.2022 Koelblgasse 8-10, 67640 Fegersheim 1030, Vienna, Austria Help S.A ,10 ambroxol Help S.A. Pedini, Valaoritou str., GR 6mg/ml, 09.03.2016 3 Abrobion (ambroxol syrup Ioanninon, Ioannina, Greece R05CB06 15404 OTC3 144 52, 125ml glass bottle 09.03.2021 hydrochloride) 45500 Metamorphosis, Attika, Greece Salutas Pharma GmbH, Otto-von- Guericke-Alle-1, 100mg/5ml, 39179 Barleben-batch Sandoz 30g powder in 75ml glass powder for oral releaser, Allphamed Pharmaceuticals d.d., bottle and measuring 20.10.2015 4 ACC acetylcysteine solution with orange Pharbil Arzneimittel Germany R05CB01 14947 OTC Verovskova Str. 57, spoon 5ml, 60g powder in 20.10.2020 flavour GmbH Hildebrandstr. 1000 Ljubljana, 150ml glass bottle and 12, 37081 Gottingen, Slovenia measuring spoon 5ml Germany-bulk manufacturer, packager 1 Salutas Pharma GmbH, Otto-von- Guericke-Alle-1, 39179 Barleben - Sandoz batch releaser Pharmaceuticals d.d., 100mg, 21.11.2014 5 ACC 100 acetylcysteine tablets effervescent (Hermes Pharma Germany R05CB01 13967 OTC Verovskova Str.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau Et Al
    US 20150202317A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau et al. (43) Pub. Date: Jul. 23, 2015 (54) DIPEPTDE-BASED PRODRUG LINKERS Publication Classification FOR ALPHATIC AMNE-CONTAINING DRUGS (51) Int. Cl. A647/48 (2006.01) (71) Applicant: Ascendis Pharma A/S, Hellerup (DK) A638/26 (2006.01) A6M5/9 (2006.01) (72) Inventors: Harald Rau, Heidelberg (DE); Torben A 6LX3/553 (2006.01) Le?mann, Neustadt an der Weinstrasse (52) U.S. Cl. (DE) CPC ......... A61K 47/48338 (2013.01); A61 K3I/553 (2013.01); A61 K38/26 (2013.01); A61 K (21) Appl. No.: 14/674,928 47/48215 (2013.01); A61M 5/19 (2013.01) (22) Filed: Mar. 31, 2015 (57) ABSTRACT The present invention relates to a prodrug or a pharmaceuti Related U.S. Application Data cally acceptable salt thereof, comprising a drug linker conju (63) Continuation of application No. 13/574,092, filed on gate D-L, wherein D being a biologically active moiety con Oct. 15, 2012, filed as application No. PCT/EP2011/ taining an aliphatic amine group is conjugated to one or more 050821 on Jan. 21, 2011. polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeu (30) Foreign Application Priority Data tically useful half-lives. The invention also relates to pharma ceutical compositions comprising said prodrugs and their use Jan. 22, 2010 (EP) ................................ 10 151564.1 as medicaments. US 2015/0202317 A1 Jul. 23, 2015 DIPEPTDE-BASED PRODRUG LINKERS 0007 Alternatively, the drugs may be conjugated to a car FOR ALPHATIC AMNE-CONTAINING rier through permanent covalent bonds.
    [Show full text]
  • Substance Abuse by Adolescents in 1977 with 499 French Adolescents
    In a country like Israel, which is deeply committed to the main sources of infection, among them active foci achievement of an expanded immunization program, the still present in the neighboring territories. effort to reach this objective should be weighed within the national program aimed at elimination of the diseases References .................................. controlled by mass immunization. Analysis of present achievements clearly shows that measles, together with 1. Swartz, T. A., and Klingberg, W.: Routine measles immu- poliomyelitis and rubella, deserves to be included among nization in Israel: A three-year clinical and serologic follow- up. In International conference on application of vaccines the first priorities of a program whose objective is elim- against viral, rickettsial, and bacterial diseases of man, ination of clinical disease. Washington, D.C., 14-18 December 1970. Pan American Health Organization, Washington, D.C., 1971, pp. Conclusions 265-268. 2. Centers for Disease Control: Measles Surveillance Report No. 11, 1977-1981. Atlanta, Ga., September 1982. A 17-year-old immunization program has created the 3. Health and Welfare Canada: Measles in Canada. Canada basis for elimination of measles in Israel, provided that Diseases Weekly Report 9-25: 29-101 (1983). (a) the control policy is adapted to the seroepidemiology 4. World Health Organization: Measles surveillance. Weekly of the infection, and (b) a concentrated logistic effort is Epidemiol Record 58: 85-86 (1983). mounted in the period preceding the next expected epi- 5. Hopkins, D. R., Hinman, A. R., Kaplan, J. E, and Lane, J. M.: The case for global measles eradication. Lancet 1: demic. Under this effort: 1936-1938, June 19, 1982.
    [Show full text]
  • DOCUMENT RESUME ED 222 832 CG 016 300 AUTHOR Lettieri, Dan
    DOCUMENT RESUME ED 222 832 CG 016 300 AUTHOR Lettieri, Dan J., Ed.; Ludford, Jacqueline P., Ed. TITLE Drug Abuse and the American Adolescent. NIDA Research Monograph 38. A RAUS Review Report. INSTITUTION National Inst. on Drug Abuse (DHHS), Rockville, Md. Div. of Research. REPORT NO DHHS-ADM-81-1166 PUB DATE 8 Sep 80 NOTE 140p.; Papers presented at the Research Analysis and Utilization System (RAUS) Review Conference on Drug Abuse and the American Adolescent (Rockville, MD, September 8, 1980). AVAILABLE FROMSuperintendent of Documents, U.S. Government Printing Office, Washington, DC 20402. PUB TYPE Collected Works - Conference Proceedings (021) Reference Materials - Bibliographies (131) Reports Research/Technical (143) EDRS PRICE MF01/PC06 Plus Postage. DESCRIPTCRS *Adolescents; Biomedicine; Cohort Analysis; *Delinquent Behavior; Drinking; *Drug Abuse; Individual Differences; Literature Reviews; Longitudinal Studies; *Peer Influence; Personality Traits; *Predictor Variables; Secondary Education; *Youth Problems IDENTIFIERS *Epidemiology ABSTRACT This report reviews five studiei-dealing with drug abuse and adolescence and presents an overview of the social changes which have contributed to the increased use of marijuana and other illicit drugs. The importance of the longitudinal study as a research tool is emphasized in describing the research projects that dealwith the epidemiology of drug use, personality and sociodemographic factors, peer influence, the relationship between delinquency and drug use, and its biomedical consequences. The report closes with an executive summary, discussion, and suggestions for further research. An annotated list of NIDA (National Institute of DrugAbuse) research monographs is included. (JAC) *********************************************************************** Reproductions supplied by EDRS are the best that can be made from the original document. *********************************************************************** Drug Abuse and the American Adolescent Editors: Dan J.
    [Show full text]
  • Efficacy of Peptide Anxiolytic Selank During Modeling of Withdrawal Syndrome in Rats with Stable Alcoholic Motivation
    52 Bulletin of Experimental Biology and Medicine, Vol. 157, No. 1, May, 2014 PHARMACOLOGY AND TOXICOLOGY Effi cacy of Peptide Anxiolytic Selank during Modeling of Withdrawal Syndrome in Rats with Stable Alcoholic Motivation L. G. Kolik, A. V. Nadorova, and M. M. Kozlovskaya Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 1567, No. 1, pp. 61-65, January, 2014 Original article submitted January 31, 2013 We studied the effects of selank on the development of symptoms of acute 48-h alcohol withdrawal in outbred rats drinking 10% ethanol as the only source of fl uid for 24 weeks. In alcohol-preferring animals (mean daily ethanol intake >5.0 g/kg) allowed free choice between 10% ethanol and water, single intraperitoneal injection of selank in a dose of 0.3 mg/kg eliminated anxiety induced by ethanol withdrawal in tests elevated plus maze and so- cial interaction tests and prevented the formation of mechanical allodynia without affecting ethanol consumption. The fi ndings suggest that selank is effective in eliminating of alcohol withdrawal symptoms in rats. Key Words: selank; alcohol withdrawal; anxiety; allodynia; rats Benzodiazepine anxiolytics temporary relieving man- by rapid onset of therapeutic effect and the absence of ifestation of psychopathological symptoms associ- undesirable side effects [4]. Experimental studies have ated with withdrawal syndrome play an important shown that it had a broad spectrum of psychotropic role in the complex medical therapy for alcoholism. activity and restored integrative activity of the CNS However, numerous side effects, such as respiratory impaired by neurotoxic factors of different genesis depression, excitement, potentiation of the narcogene [5].
    [Show full text]
  • Фармакология Pharmacology
    МИНИСТЕРСТВО ЗДРАВООХРАНЕНИЯ РЕСПУБЛИКИ БЕЛАРУСЬ БЕЛОРУССКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ КАФЕДРА ФАРМАКОЛОГИИ ФАРМАКОЛОГИЯ PHARMACOLOGY Практикум для специальности «Лечебное дело» 5-е издание, переработанное Минск БГМУ 2020 2 УДК 615(076.5)(075.8)-054.6 ББК 52.81я73 Ф24 Рекомендовано Научно-методическим советом университета в качестве практикума 29.05.2020 г., протокол № 9 А в т о р ы: проф. Н. А. Бизунок, проф. Б. В. Дубовик, доц. Б. А. Волынец, доц. А. В. Волчек Р е ц е н з е н т ы: д-р мед. наук, проф. А. В. Хапалюк; д-р. мед. наук, проф. А. И. Волотовский Фармакология = Pharmacology : практикум для специальности «Лечебное дело» / Ф24 Н. А. Бизунок [и др.]. – 5-е изд., перераб. – Минск : БГМУ, 2020. – 156 с. ISBN 978-985-21-0643-6. Содержит методические рекомендации для подготовки к лабораторным занятиям по фармакологии и задания для самостоятельной работы студентов, обучающихся по специальности 1-79 01 01 «Лечебное дело». Первое издание вышло в 2016 году. Предназначен для студентов 3-го курса медицинского факультета иностранных учащихся, изучающих фармакологию на английском языке. УДК 615(076.5)(075.8)-054.6 ББК 52.81я73 ISBN 978-985-21-0643-6 © УО «Белорусский государственный медицинский университет», 2020 3 CONTENTS INTRODUCTION ............................................................................................................................................................. 4 GENERAL PRESCRIPTION ...........................................................................................................................................
    [Show full text]